Naltrexone for impulse control disorders in parkinsons disease
Naltrexone, a long-acting opioid receptor antagonist, helps in the treatment of alcohol and opioid dependence.
Tribute Pages What is a Tribute Page? The primary objective for this study was to assess the efficacy of naltrexone for the treatment of ICDs in PD. Willingness to maintain existing PD pharmacotherapy regimen for the duration of the study. All authors edited the manuscript for accuracy and content.
National Library of Medicine U. For the QUIP-RS, scores for each compulsive behavior range from 0 to 16, with a higher score indicating greater severity frequency of symptoms. Talk with your doctor and family members or friends about deciding to join a study. Get helpful advice on your cases from a community of physicians. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: Impulse Control Disorder Parkinson Disease.
In addition, other novel treatments to be considered for this condition include medications targeting glutamate another brain chemical and the possibility of deep brain stimulation. Impulse control disorders ICDs; compulsive gambling, buying, sexual behavior, and eating occur relatively frequently in Parkinson disease PD. American Psychiatric Association; Patients may be reluctant to discontinue DA treatment due to the motor benefits derived from treatment, so patients often have chronic symptoms.
An unstructured, clinician-completed D. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The completers analyses were consistent with the intent-to-treat analyses. The Clinical Global Impression-Improvement scale rates total improvement on a 7 point scale:.
Participants not in response at week 4 were increased to mg per day for the remaining four weeks of the study. Better navigate the business aspects of medicine and stay on top of the changing healthcare landscape. Generate a file for use with external citation management software.
See comment in PubMed Commons below Neurology.
The results of this study were negative for the efficacy of naltrexone for the treatment of ICDs in PD using a clinician-based rating of global improvement. Joint Accredited with multiple accreditations, including:.
Standard protocol approvals, registrations, and patient consents. This would have significant treatment implications for the relatively large number of PD patients suffering from one or more ICDs, who currently have no treatment option other than to stop or decrease their DA treatment. A total of 48 patients provided adverse event data.